The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
On October 3, 2024, Teva Pharmaceuticals and mAbxience, a Fresenius Kabi majority-owned group, announced a new global licensing agreement for the development of an anti PD-1 oncology biosimilar ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
On December 22, 2025, the FDA approved mAbxience and Amneal’s Biologics Licensing Applications (BLAs) for BONCRESA™ (denosumab-mobz) and OZILTUS™ (denosumab-mobz), biosimilars referencing Amgen’s ...
TEL AVIV, Israel, & MADRID--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority ...
mAbxience secures its second 4,000L ABEC Custom Single Run (CSR®) bioreactor to increase manufacturing capacity at its Leon, Spain facility BETHLEHEM, Pa.--(BUSINESS WIRE)--ABEC, a global provider of ...
(RTTNews) - Teva Pharmaceuticals International GmbH, a unit of Teva Pharmaceutical Industries Ltd. (TEVA) and mAbxience have entered a strategic licensing agreement for a biosimilar candidate ...
Genedata, a Danaher company and the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that mAbxience has selected the Genedata Bioprocess ® enterprise ...
Agreement comes as Teva aims to strengthen its biosimilar portfolio as part of its "Pivot to Growth" strategy. Teva Pharmaceuticals and mAbxience have announced a major strategic licensing deal for a ...
mAbxience utilizing ABEC Custom Single Run (CSR) technology to increase flexibility and productivity ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing, ...
mAbxience secures its second 4,000L ABEC Custom Single Run (CSR®) bioreactor to increase manufacturing capacity at its Leon, Spain facility In April 2022, and after being approved in Europe, Canada, ...
mAbxience / Key word(s): Joint Venture/Product Launch 04.12.2025 / 09:05 CET/CEST The issuer is solely responsible for the content of this announcement. MADRID, Dec. 4, 2025 /PRNewswire/ -- mAbxience, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results